NEW YORK (GenomeWeb News) – Myriad Genetics announced that it will build a new laboratory at its Salt Lake City facility within which the company will develop companion diagnostics in line with US Food and Drug Administration's regulations.

The new lab build out, according to Myriad, expands its non-exclusive collaboration with AstraZeneca to study the drug olaparib in Phase III trials using Myriad's BRACAnalysis test to pick out best responders to the treatment. The partners did not disclose the specific terms of the expanded collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.